Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics' stock price has been significantly impacted by several events in the past six months. The stock jumped 36.3% following the announcement of plans to initiate a pivotal Phase 2 trial for vopimetostat monotherapy in second-line MTAP-deleted pancreatic cancer during 2026, supported by positive Phase 1/2 clinical data. Other contributing factors included a clinical collaboration with Erasca, strong growth in collaboration revenue, and presentations at major healthcare conferences. Analyst firms have also shown strong support, with several increasing their price targets for TNGX shares. The stock has seen a remarkable 1,965% return over the past year. On April 15, 2026, the President of R&D, Crystal Adam, exercised stock options and subsequently sold shares.

As a clinical-stage biotechnology company focused on developing cancer therapies, Tango Therapeutics' products are still in development and not yet commercially available. Therefore, traditional demand seasonality does not apply. The demand for its future products, once approved, would likely be driven by medical need and treatment efficacy rather than seasonal patterns.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology therapies, identifying novel drug targets, and delivering next-generation medicines for cancer treatment, particularly in defined patient populations with unmet medical needs. The company's major product candidates are primarily methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trials for non-central nervous system (CNS) cancers, and TNG456, a brain-penetrant PRMT5 inhibitor for CNS cancers. Tango Therapeutics is also developing TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor, and vopimetostat, a synthetic lethal small molecule inhibitor.

Tango Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States. The company was founded in 2017 and is incorporated in Delaware.

Tango Therapeutics' brand reputation has been positively influenced by advancements in its clinical programs and strong analyst support in the past year. The announcement of a pivotal Phase 2 trial for vopimetostat and positive clinical data has been a significant reputational boost. Strategic collaborations, such as the one with Erasca, and positive combination study data have also contributed to a favorable perception. Furthermore, consistent backing from financial analysts, including increased price targets, reflects a positive outlook on the company's potential in precision oncology. The company's participation in major healthcare conferences also helps maintain visibility and communicate progress to the scientific and investment communities.

Tango Therapeutics, Inc. has significant institutional ownership, with 180 institutional owners and shareholders holding a total of 152,693,730 shares. Major institutional owners include Farallon Capital Management Llc, Boxer Capital Management, LLC, Adage Capital Partners Gp, L.l.c., Woodline Partners LP, BlackRock, Inc., Siren, L.L.C., Trv Gp Iv, Llc, Vanguard Group Inc, State Street Corp, and Balyasny Asset Management Llc. Ecor1 Capital LLC is noted as the largest individual shareholder, owning 23.96 million shares, representing 16.79% of the company. Overall, institutional shareholders hold 120.82% of Tango Therapeutics stock, while insiders hold 58.28%, and retail investors hold 0.00%.